HIV/AIDS-TB患者抗结核药物治疗强化期红细胞系的变化
作者:
作者单位:

作者简介:

董兴齐

通讯作者:

中图分类号:

R512.91;R521

基金项目:

云南省科技计划(重点新产品开发)(2016BC005)


Changes in erythrocyte lineage in patients with HIV/AIDS-TB during intensive period of therapy with antituberculosis drugs
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 文章评论
    摘要:

    目的 分析接受抗逆转录病毒治疗(ART)及不同ART方案联合抗结核药物治疗的人类免疫缺陷病毒/艾滋病合并结核分枝杆菌感染(HIV/AIDS-TB)患者在强化期内血液学红细胞系的变化情况。方法 选取2014-2017年某传染病专科医院确诊为HIV/AIDS-TB的患者,分为在ART基础上接受抗结核药物联合治疗组(A组),抗结核药物治疗8周内开始ART联合治疗组(B组),抗结核药物治疗8周后开始ART治疗组(C组);检测并比较治疗前基线(0周)和治疗后1、2、4、8周等红细胞系参数红细胞(RBC)、血红蛋白(HGB)、红细胞平均体积(MCV)和红细胞分布宽度(RDW-CV)变化的差异。结果 共选取180例HIV/AIDS-TB患者,其中A组71例、B组75例、C组34例;共85.00%(153例)的患者发生轻度贫血,其中A、B、C组分别为84.51%(60/71)、85.33%(64/75)和85.29%(29/34)。抗结核药物治疗后,A、B和C组患者RBC绝对值增减差异均无统计学意义(均P>0.05);治疗4周后,B组患者HGB增加均高于基线(均P<0.05);A、B和C组患者MCV和RDW-CV在治疗后均较基线上升(均P<0.05),但C组治疗8周时RDW-CV恢复至基线水平。A、B两组患者中TDF/3TC/EFV方案在联合抗结核药物治疗4周时,HGB均较基线增高(均P<0.05),其他方案均无统计学意义(均P>0.05)。结论 HIV/AIDS-TB患者在抗结核药物治疗后应尽快启动ART治疗,最好8周内开始ART治疗,不同ART方案联合抗结核治疗患者的红细胞系参数变化有差异,TDF治疗方案效果较为理想。

    Abstract:

    Objective To analyze changes in hematological erythrocyte lineage in patients with HIV/AIDS and Mycobacterium tuberculosis infection (HIV/AIDS-TB) during intensive period of antiretroviral therapy (ART) and different ART regimens combined with anti-tuberculosis drugs. Methods Patients who were confirmed with HIV/AIDS-TB in an infectious disease hospital from 2014 to 2017 were selected and divided into three groups:group A received combination therapy of anti-tuberculosis drugs on the basis of ART, group B started ART within 8 weeks of anti-tuberculosis drug therapy, group C started ART after 8 weeks of anti-tuberculosis drug therapy; changes in parameters of erythrocyte lineage, such as red blood cell(RBC), hemoglobin(HGB), mean corpuscular volume(MCV), and RBC distribution width (RDW-CV) before therapy(baseline, at 0 week) and 1, 2, 4, and 8 weeks after therapy were detected and compared. Results A total of 180 patients with HIV/AIDS-TB were enrolled, group A, B, and C were 71, 75, and 34 cases respectively; 85.00% (n=153) of patients developed mild anemia, 84.51% (60/71), 85.33% (64/75), and 85.29% (29/34) were in group A, B, and C respectively. After anti-tuberculosis drug therapy, changes in absolute value of RBC in group A, B, and C had no significant difference (all P>0.05); after 4 weeks of therapy, increase of HGB in patients in group B was higher than baseline (P<0.05); MCV and RDW-CV in group A, B, and C after therapy were all higher than baseline (all P<0.05), but RDW-CV in group C recovered to baseline level at 8 weeks of therapy. HGB of group A and B at 4 weeks of TDF/3TC/EFV regimen combined anti-tuberculosis drug therapy were both higher than that of baseline (both P<0.05), but there was no significant difference in other regimens (all P>0.05). Conclusion Patients with HIV/AIDS-TB should start ART as soon as possible after anti-tuberculosis drug therapy, preferably within 8 weeks, changes in erythrocyte parameters in patients treated with different ART regimens combined with anti-tuberculosis therapy are different, effect of TDF therapy is ideal.

    参考文献
    相似文献
引用本文

舒远路, 杨翠先, 张米,等. HIV/AIDS-TB患者抗结核药物治疗强化期红细胞系的变化[J]. 中国感染控制杂志,2019,18(5):396-402. DOI:10.12138/j. issn.1671-9638.20194404.
SHU Yuan-lu, YANG Cui-xian, ZHANG Mi, et al. Changes in erythrocyte lineage in patients with HIV/AIDS-TB during intensive period of therapy with antituberculosis drugs[J]. Chin J Infect Control, 2019,18(5):396-402. DOI:10.12138/j. issn.1671-9638.20194404.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2018-11-14
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2019-05-28
  • 出版日期: